Gravibinan Inj 1 Ampx2 ml. is primarily indicated in conditions like Menopausal symptoms, Prostatic cancer.
Gravibinan Inj 1 Ampx2 ml . is contraindicated in conditions like Hypertension, Vaginal bleeding, Porphyrias, Cardiovascular disease,Oestrogenic sarcoma,Cerebrovascular disease, Haemoglobinopathies, Hyperlipoprotein aemia.
The severe or irreversible adverse effects of Gravibinan Inj 1 Ampx2 ml, which give rise to further complications include Irritability, Gynacomastia, Uterine bleeding, Tachyphylaxis.Gravibinan Inj 1 Ampx2 ml produces potentially life-threatening effects which include Breast cancer, Endometrial carcinoma. which are responsible for the discontinuation of Gravibinan Inj 1 Ampx2 ml therapy. The symptomatic adverse reactions produced by Estradiol, are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Depression, Weight gain, Nausea and vomiting, Fluid retention, Breast tenderness.
High doses of estrogen used in treatment of malignant disease should be used cautiously in patients with cerebrovascular disorder, coronary artery disease or venous thromboembolism. Estrogens should be used with caution in children, because premature closure of epiphysis may occur resulting in inhibited linear growth and small stature.